Erfahrungsheilkunde 2020; 69(01): 24-30
DOI: 10.1055/a-1098-7212
Wissen

Phytotherapie bei koronarer Herzkrankheit – Was gibt es an Evidenz?

Peter W. Gündling

Zusammenfassung

Obgleich der Schwerpunkt der naturheilkundlichen Behandlung der koronaren Herzkrankheit (KHK) bei nicht medikamentösen Maßnahmen wie der Ernährungs- und Bewegungstherapie, den Entspannungsverfahren und der Hydrotherapie liegt, spielen auch Phytotherapeutika eine wichtige Rolle. Umfragen zeigen, dass nahezu jeder 2. Patient mit KHK auch pflanzliche Präparate einnimmt. Unterstützend zum traditionellen Erfahrungswissen gab es in den letzten Jahren zunehmend wissenschaftliche Belege, die in diesem Beitrag dargestellt werden.

Abstract

Although the focus of the naturopathic treatment of coronary heart disease (CHD) is on non-drug measures such as nutritional and movement therapy, relaxation techniques and hydrotherapy, phytotherapeutics also play an important role. Surveys show that almost every 2nd patient with CHD also takes herbal preparations. In support of traditional empirical knowledge, there has been increasing scientific evidence in recent years, which is presented in this article.



Publikationsverlauf

Artikel online veröffentlicht:
19. Februar 2020

© MVS Medizinverlage Stuttgart GmbH & Co. KG
Stuttgart · New York

 
  • Literatur

  • 1 Rabito MJ, Kaye AD. Complementary and alternative medicine and cardiovascular disease: An evidence-based review. Evid-Based Compl Altern Med 2013; 672097: 8 http://dx.doi.org/10.1155/2013/672097
  • 2 Grant SJ, Bin YS, Kiat H. et al. The use of complementary and alternative medicine by people with cardiovascular disease: A systematic review. BMC Public Health 2012; 26: 299
  • 3 Gündling PW. Brennpunkt Herz. Natürlich heilen und vorbeugen bei Herz-Kreislauf-Problemen. Baden-Baden: Aurelia; 2004
  • 4 Gündling PW. Herz- und Gefäßschutz. Was leisten nichtmedikamentöse Maßnahmen?. Der Allgemeinarzt 2007; 29 (02) 6-9
  • 5 Nationale Versorgungsleitlinie Chronische Herzinsuffizienz. Version 1.4. 2011
  • 6 Mashour NH, Lin GI, Frishman WH. Herbal medicine for the treatment of cardiovascular disease: Clinical considerations. Arch Intern Med 1998; 158 (20) 2225-2234
  • 7 Gündling PW. Phytotherapie bei Herz-Kreislauf-Krankheiten. Arzt Zahn Naturh 2010; 1: 5-9
  • 8 Rastogi S, Pandey MM, Rawat AKS. Traditional herbs: A remedy for cardiovascular disorders. Phytomedicine 2016; 23 (11) 1082-1089
  • 9 Mahmood ZA, Sualeh M, Mahmood SB. et al. Herbal treatment for cardiovascular disease: The evidence based therapy. Pak J Pharm Sci 2010; 23 (01) 119-124
  • 10 Dwivedi S, Chopra D. Revisiting Terminalia arjuna – An Ancient Cardiovascular Drug. J Tradit Complement Med 2014; 4 (04) 224-231
  • 11 Kapoor D, Vijayvergiya R, Dhawan V. Terminalia arjuna in coronary artery disease: Ethnopharmacology, pre-clinical, clinical & safety evaluation. J Ethnopharmacol 2014; 155: 1029-1045
  • 12 Bhawania G, Kumar A, Murthy KS. et al. A retrospective study of effect of Terminalia arjuna and evidence based standard therapy on echocardiographic parameters in patients of dilated cardiomyopathy. J Pharm Res 2013; 6: 493-498
  • 13 Dwivedi S, Aggarwal A, Agarwal MP. et al. Role of Terminalia arjuna in ischaemic mitral regurgitation. Int J Cardiol 2005; 100: 507-508
  • 14 Malik N, Dhawan V, Bahl A. et al. Inhibitory effects of Terminalia arjuna on platelet activation in vitro in healthy subjects and patients with coronary artery disease. Platelets 2009; 20: 183-190
  • 15 Pingali U, Fatima N, Nizampatnam M. Evaluation of Terminalia arjuna on cardiovascular parameters and platelet aggregation in patients with Type II diabetes mellitus. Res J Life Sci 2013; 1: 7-12
  • 16 Tripathi VK, Singh B, Jha RN. et al. Studies on Arjuna in coronary heart disease. J Res Ayur Siddha 2000; 21: 37-40
  • 17 Kumar G, Srivastava A, Sharma SK. et al. Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and ArogyavardhiniVati) in dyslipidemia patients: A pilot prospective cohort clinical study. Ayu 2012; 33: 197-201
  • 18 Shang A, Cao SY, Xu XY. et al. Bioactive compounds and biological functions of Garlic (Allium sativum L.). Foods. 2019 doi:10.3390/foods8070246
  • 19 Sobenin IA, Myasoedova VA, Iltchuk MI. et al. Therapeutic effects of garlic in cardiovascular atherosclerotic disease. Chin J Nat Med 2019; 17 (10) 721-728
  • 20 Wlosinska M, Nilsson AC, Hlebowicz J. et al. Aged garlic extract preserves cutaneous microcirculation in patients with increased risk for cardiovascular diseases: A double-blinded placebo-controlled study. Int Wound J 2019; 16 (06) 1487-1493
  • 21 Zhao R, Xie E, Yang X. et al. Alliin alleviates myocardial ischemia-reperfusion injury by promoting autophagy. Biochem Biophys Res Commun 2019; 512 (02) 236-243
  • 22 Liu J, Zhang G, Cong X. et al. Black Garlic Improves Heart Function in Patients With Coronary Heart Disease by Improving Circulating Antioxidant Levels. Front Physiol 2018; 9: 1435 doi:10.3389/fphys.2018.01435
  • 23 Siddiqui NA, Haider S, Misbah-ur-Rehman M. et al. Role of herbal formulation of garlic on lipidprofile in patients with type 2 diabetes related dyslipidemia. Pak Heart J 2016; 49: 146-150
  • 24 Ho XL, Tsen SY, Ng MY. et al. Aged garlic supplement protects against lipidperoxidation in hypercholesterolemic individuals. J Med Food 2016; 19: 931-937
  • 25 Stabler SN, Tejani AM, Huynh F. et al. Garlic for the prevention of cardiovascular morbidity and mortality in hypertensive patients. Coch Data Syst Rev 2012; 8: CD007653
  • 26 Zhao H, Han Z, Li G. et al. Therapeutic potential and cellular mechanisms of Panax Notoginseng on prevention of aging and cell senescence-associated diseases. Aging Dis 2017; 8 (06) 721-739
  • 27 Karmazyn M, Moey M, Gan XT. Therapeutic potential of ginseng in the management of cardiovascular disorders. Drugs 2011; 71 (15) 1989-2008
  • 28 Dong Y, Duan L, Chen HW. et al. Network pharmacology-based prediction and verification of the targets and mechanism for Panax notoginseng saponins against coronary heart disease. Evid Based Complement Alternat Med 2019; 6503752 doi:10.1155/2019/6503752
  • 29 Park BJ, Lee YJ, Lee HR. et al. Effects of Korean red ginseng on cardiovascular risks in subjects with metabolic syndrome: A double-blind randomized controlled study. Kor J Family Med 2012; 33: 190-196
  • 30 Gündling PW. Weißdorn – Neue Erkenntnisse zu einer alten Heilpflanze. Erfahrungsheilk 2017; 66 (04) 36-43
  • 31 Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: An evidence-based approach. Evid Based Complement Alternat Med 2013; 149363 doi:10.1155/2013/149363
  • 32 Orhan IE. Phytochemical and pharmacological activity profile of Crataegus oxyacantha L. (Hawthorn) – A cardiotonic herb. Curr Med Chem 2018; 25 (37) 4854-4865
  • 33 Koch E, Malek FA. Standardized extracts from Hawthorn leaves and flowers in the treatment of cardiovascular disorders – preclinical and clinical studies. Planta Medica 2011; 77 (11) 1123-1128
  • 34 Wegener T, Gündling PW, Holubarsch CJF. et al. Stellenwert von Weißdornextrakt in der hausärztlichen Praxis — eine aktuelle Standortbestimmung. MMW Fortschr Med 2018; 160 (04) 1-7
  • 35 Wegener T. Weißdorn Extrakt – Aktuelle Erkenntnisse zum Wirkprinzip. Phytokompass 2016; 5: 20-23
  • 36 Waimer F, Stumpf H. Qualität quantifizierter Pflanzenextrakte. Dt Apoth Z 2006; 146: 1842-1847
  • 37 Zorniak M, Szydlo B, Krzeminski TF. Crataegus special extract WS 1442: Up-to-date review of experimental and clinical experiences. J Physiol Pharmacol 2017; 68 (04) 521-526
  • 38 Tassell M, Kingston R, Gilroy D. et al. Crataegus spp. in the treatment of cardiovascular disease. Pharmacog Rev 2010; 4 (07) 32-41
  • 39 Koch E. et al. Crataegus extract WS®-1442 enhances coronary flow in the isolated rat heart by endothelial release of nitric oxide. Naunyn-Schmiedeberg’s Arch Pharmacol 2000; 361: R48
  • 40 Brixius K, Willms S, Napp A. et al. Crataegus special extract WS 1442 induces an endothelium-dependent, NO-mediated vasorelaxation via eNOS-phosphorylation at serine 1177. Cardiovasc Drugs Ther 2006; 20 (03) 177-184
  • 41 Idris-Khodja N, Auger C, Koch E. et al. Crataegus special extract WS® 1442 prevents aging-related endothelial dysfunction. Phytomed 2012; 19 (08/09) 699-706
  • 42 Veveris M, Koch E, Chatterjee SS. Crataegus special extract WS 1442 improves cardiac function and reduces infarct size in a rat model of prolonged coronary ischemia and reperfusion. Life Sci 2004; 74 (15) 1945-1955
  • 43 Swaminathan JK, Khan M, Mohan IK. et al. Cardioprotective propiertes of Crataegus Oxycantha against ischemia-reperfusion injury. Phytomed 2010; 17: 744-752
  • 44 Xia N, Weisenburger S, Koch E. et al. Restoration of perivascular adipose tissue function in diet-induced obese mice without changing bodyweight. Br J Pharmacol 2017; 174 (20) 3443-3453